Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | The MAGIC model: a day 14 endpoint for acute GvHD clinical trials

James Ferrara • 16 Apr 2024
EBMT 2024
General

James Ferrara, MD, DSc, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, introduces the MAGIC model, which considers clinical features and biomarkers to predict outcomes of treatment for acute graft-versus-host disease (GvHD). This model can predict outcomes at day 14 of treatment more accurately than previous models which only consider clinical features. Dr Ferrara suggests day 14 should be a new endpoint in GvHD clinical trials. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

I hold a patent for serum biomarkers of acute GVHD which is licensed and for which I receive royalties.

More from James Ferrara

1:15
Reducing steroid usage in the treatment of lower-risk GvHD
James Ferrara • 16 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes at the onset of GvHD
James Ferrara • 16 Apr 2024
0:46
ST2 and REG3α as predictive biomarkers for GvHD
James Ferrara • 24 Apr 2023
1:54
A novel clinical trial endpoint for acute GvHD
James Ferrara • 24 Apr 2023

Related Videos

4:09
Veno-occlusive disease as a post-transplant complication of HSCT
Mohamad Mohty • 17 Apr 2024
1:56
Addressing access inequality in CAR-T therapies
Francesca Del Bufalo • 15 Apr 2024
1:34
The future role of AI models in hematology and the need for high-quality data sets
Thomas Coats • 29 Apr 2024
6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals